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OVERVIEW OF RESEARCH DESIGN IN 
EPIDEMIOLOGY 
John Concato, M.D., M.S., M.P.H.* 
INTRODUCTION 
The objectives of this paper are to first, provide background 
regarding a conceptual model of causality in epidemiology; 
second, describe common types of structure (architecture) used for 
research design in epidemiology, including descriptive, cohort, 
case-control, and cross-sectional studies; third, review frequently-
encountered formats for reporting the results of such studies; and 
fourth, discuss the strengths and limitations of strategies used in 
epidemiology. The first and fourth objectives represent a big-
picture assessment for interpreting epidemiologic studies; whereas 
the second and third objectives promote a nuts-and-bolts 
understanding of the studies themselves. 
I. CONCEPTUAL MODEL OF CAUSALITY 
A discussion of research design involves considerations of the 
concept of causality, i.e., what causes disease.1 In this context, 
                                                          
 * The author is an Associate Professor of Medicine in the Department of 
Internal Medicine at Yale University School of Medicine in New Haven, CT, 
and Director of the Clinical Epidemiology Research Center at VA Connecticut 
Healthcare System in West Haven, CT. The conclusions and opinions expressed 
in this article are those of the author and do not represent any official or 
unofficial position of Yale University or the U.S. Department of Veterans 
Affairs. Presented at the second Science for Judges Symposium, Brooklyn Law 
School, Brooklyn, NY, November 7, 2003. 
1 See, e.g., Sir Austin Bradford-A.B. Hill, The Environment and Disease: 
Association or Causation?, 58 PROC. R. SOC. MED. 295-300 (1965). 
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biological phenomena can be considered either deterministic or 
probabilistic. A deterministic situation exists when the exposure 
can be linked conclusively to an outcome (e.g., when a particular 
genetic rearrangement causes sickle cell anemia). In contrast, a 
probabilistic phenomenon occurs when exposure is said to be 
associated with an outcome (e.g., if hypertension (high blood 
pressure) is associated with stroke). In the first example, the 
genetic problem is always found with the disease, and vice versa. 
In the second example, hypertension increases the probability of 
stroke; but some patients with hypertension do not suffer a stroke, 
and some patients with stroke do not have antecedent hypertension. 
A major role of epidemiological research design is to provide 
information for, or against, a probabilistic association. A 
conceptual (intellectual) model2 has been developed for this 
purpose, and is often described with terms such as cause-effect 
research (Figure 1). The entity being evaluated as a possible cause 
of a disease, or other endpoint, is referred to as an exposure, but is 
not limited to environmental exposures, and can include a person’s 
age, sex, personal habits (such as cigarette smoking), ingested 
medications, etc. The entity being assessed as a possible disease or 
other endpoint is referred to as an outcome, and can include the 
development of a disease, a quality of life measurement, death, etc. 
 
FIGURE 1—CONCEPTUAL MODEL FOR CAUSE-EFFECT RESEARCH 
 
      Baseline state      →      Exposure     →      Outcome 
     Condition prior         Factor(s) that              Disease 
        to exposure                may lead                or entity 
        or outcome             to outcome                of interest 
 
Example: 
       Healthy adults     →    Hypertension  →        Stroke 
 
The model can be applied to the association of hypertension 
and stroke, addressing the question of whether hypertension can 
                                                          
2 ALVAN R. FEINSTEIN, CLINICAL EPIDEMIOLOGY: THE ARCHITECTURE OF 
CLINICAL RESEARCH 50 (Saunders 1985). 
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“cause” stroke (in a probabilistic, not a deterministic, sense). In 
this example, adults, either with or without hypertension, do or do 
not develop subsequent stroke. The challenge involves determining 
whether stroke is more common among patients with hypertension; 
and if so, whether the corresponding evidence (in the form of data) 
is strong enough, and stable enough, to confirm that an association 
exists and is “real.” 
A useful aspect of cause and effect studies is the ability to 
summarize the association of interest with a simplified schematic 
(2 × 2 table) showing the relationship of exposure and outcome 
(Table 1A). Although most epidemiological investigations involve 
more complex designs, the focus of a study can be understood 
using this approach. This framework will be used throughout the 
subsequent text, with each of the types of research architecture, to 
demonstrate basic principles involved. 
 
TABLE 1A—SCHEMATIC OF CAUSE-EFFECT STUDY 
 
Exposure
No exposure
Outcome  No outcome
Exposure = factor that may “cause” outcome 
Outcome = entity (e.g., disease) of interest
a             b
c             d
 
II.  SPECIFIC TYPES OF RESEARCH DESIGN 
Unfortunately, no universally accepted terminology 
(classification scheme) exists for types of epidemiologic studies. 
Specific terms are often used to describe basic categories and 
formats of studies (Figure 2), but the terms may vary with different 
authors, leading to potential confusion.3 
                                                          
3 For example, the terms prospective and retrospective are often used to 
describe studies, but these terms can be confusing because they are applied to 
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FIGURE 2—OVERVIEW OF RESEARCH ARCHITECTURE 
 
Epidemiological Studies
Descriptive studies “Analytic” studies
• case report/series
Observational studies Experimental studies
• cross-sectional • e.g., randomized trial
• observational cohort            (experimental cohort)
• case-control
 
A. Descriptive Studies 
The first category of research design, descriptive studies, has a 
limited role in discussions of cause-effect research because such 
studies have limited implications regarding (probabilistic) 
causation. Descriptive studies are often presented as a case report, 
or a case series of patients, and are useful to inform clinical care, 
such as a recent report describing severe acute respiratory 
syndrome (SARS).4 The strengths and limitations of descriptive 
studies in demonstrating causality is illustrated by a descriptive 
study reporting on 24 cases of valvular heart disease in patients 
taking fenfluramine-phentermine as a dietary suppressant.5 This 
article can be considered a prominent, early publication linking 
dietary suppressants and valvular heart disease. As noted in the 
discussion section of that paper, however, “ . . . definitive 
                                                          
different aspects of study architecture. In addition, I will use the association 
between dietary suppressants and heart disease hereafter in the text; I make no 
claims about the merit of any related court cases, and I do not imply to present a 
comprehensive nor complete assessment of the scientific evidence on this topic. 
Finally, I will use the term “patient” frequently, reflecting my training and 
experience as a physician; the term person may often be substituted. 
4 Nelson Lee et al., A Major Outbreak of Severe Acute Respiratory 
Syndrome in Hong Kong, 348 NEW ENG. J. MED., 1986-94 (2003). 
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statements about a true association of valvular disease with 
fenfluramine-phentermine therapy cannot be made.”5 The 
investigation corresponds to the upper left hand “cell” (labeled a) 
in Table 1B, indicating that patients with valve defects who had 
taken fenfluramine-phentermine were the focus of investigation. 
Other descriptive studies may report on patients, for example, in 
the top row of cells, but not in all four cells. The importance of this 
feature as a limitation of descriptive studies is mentioned in the 
discussion of analytic studies. 
 
TABLE 1B—EXAMPLE OF CAUSE-EFFECT STUDY 
Fen-phen
No fen-phen
Valve       No valve
defects     defects
Fenfluramine-phentermine (fen-phen) is the exposure;
valvular heart disease (valve defect) is the outcome.
a             b
c             d
 
B. Analytic Studies 
A second, and more commonly encountered, type of study can 
be described as analytic (or comparative or cause-and-effect) 
studies. This category of study is so common that the term analytic 
is not often used; alternatively, terms such as etiologic (what 
causes disease), diagnostic (how is disease diagnosed), or 
prognostic (what happens to patients with disease), are used to 
indicate the main focus of the study, rather than the architecture 
itself. 
The hallmark of analytic study is that two (or more) groups are 
compared to draw an inference regarding a cause-effect 
association. Thus, inclusion of a so-called control or comparison 
                                                          
5 Heidi M. Connolly et al., Valvular Heart Disease Associated with 
Fenfluramine-Phentermine, 337 NEW ENG. J. MED., 581-88 (1997). 
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group is an indication of an analytic study. The presence of the 
control group provides a mechanism for establishing whether the 
outcome in the exposed group occurs at a higher (vs. lower or 
similar) rate, compared with the unexposed group. 
Along with opportunity to assess (probabilistic) causation, a 
problem called analytic bias can arise in the conduct of analytic 
studies. This problem occurs if (various types of) systematic error 
exists when assessing the association of interest. For example, 
recall bias is considered a problem if certain patients do not recall 
accurately their prior exposure. Susceptibility bias is encountered 
if compared groups of persons have unequal susceptibility for the 
outcome at baseline before considering the impact of a specific 
exposure. A general term for these various sources of bias is 
confounding; a problem that exists if an extraneous factor 
interferes with assessing the relationship between exposure and 
outcome, preventing an accurate determination of the true 
magnitude of association. A possible example of confounding 
involves the question of whether ingestion of dietary suppressants 
is associated with heart disease; specifically, whether the 
association is confounded by obesity. Obesity is related 
(obviously) to ingestion of these products. The problem of 
confounding would arise if obesity were also related independently 
to valve defects—then dietary suppressants could be a “marker” 
for obesity, rather than a causal factor in the development of 
valvular heart disease. A solution in this context is to use a 
procedure (e.g., adjusting, controlling, matching) that accounts for 
confounding variables. These techniques are usually “as good as” 
the logic and measurements used in identifying potential 
confounding factors; the mathematical procedures, although 
complex, are usually not a problem themselves. 
1.  Observational Studies 
Analytic studies are typically described by another feature of 
their design; specifically, whether they are observational studies or 
experimental studies. Observational studies are investigations in 
which exposure is not assigned by a research investigator. Rather, 
the exposure occurs via “nature” or as a result of human 
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interventions in a non-research setting. For example, exposure to 
ambient air pollution would be assessed in an observational study, 
as would patients receiving certain medications in the context of 
their routine health care. Common examples of observational study 
architecture include cross-sectional, observational cohort, and case 
control studies. 
a. Cross-Sectional Studies 
The distinguishing feature of a cross-sectional study is that data 
on exposure status and outcome status are obtained at essentially 
the same point in time. In an example of a cross-sectional study, 
patients were identified from one of three previously conducted 
appetite suppressant studies, and new “control” subjects (not in the 
appetite studies) were selected based on matching on several 
factors (e.g., age, sex, physical features).6 All of the participants 
were then assessed for valvular heart disease, and the 
corresponding four cells of Table 1B would represent a 
simultaneous exposure-outcome relationship. As noted in the 
corresponding discussion section of that paper, “the purpose of the 
study was to determine the prevalence and severity of valvular 
dysfunction in obese patients who had taken appetite suppressants 
and those who had not.”6 Although antecedent appetite suppressant 
use might result in subsequent valve defects, the study architecture 
could not exclude a converse scenario with the onset of heart 
disease preceding the ingestion. Thus, the authors were suitably 
cautious regarding any claim of causation. 
b. Observational Cohort Studies 
An observational cohort study differs from a cross-sectional 
study in that it involves a longitudinal assessment, usually based 
on assembling patients with regard to their status as exposed or not 
exposed (Figure 3A). Patients’ exposure status is determined first, 
                                                          
6 Mehmood A. Khan et al., The Prevalence of Cardiac Valvular 
Insufficiency Assessed by Transthoracic Echocardiography in Obese Patients 
Treated with Appetite-Suppressant Drugs, 339 NEW ENG. J. MED., 713-18 
(1998). 
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their outcome status is determined subsequently, and then the 
association between exposure and outcome is assessed (Table 1B). 
A paragraph of an article describing the methods of an example of 
an observational cohort analysis stated that the investigators 
identified subjects who had been given fenfluramine-phentermine, 
and as a comparison group, they identified a group of subjects who 
had not received an appetite suppressant.7 The article found that the 
risk of valvular disease in subjects who had received certain 
dietary suppressants was substantially higher over a five-year 
period, indicating the ability of the study to make a claim regarding 
causality.8 
 
FIGURE 3A—SCHEMATIC OF COHORT ARCHITECTURE 
exposed
not exposed
Longitudinal assessment; start with exposure:
 
c. Case-Control Studies 
A case-control study also involves a longitudinal assessment, 
but starts with identifying patients based on their outcome status 
(Figure 3B). For example, in a case-control analysis, investigators 
compared patients with cardiac-valve abnormalities to patients 
without such abnormalities.9 Antecedent ingestion of appetite 
suppressants was then determined to establish the association of 
interest (Table 1B). The finding that longer use of fenfluramine or 
                                                          
7 H. Jick et al., A Population-Based Study of Appetite-Suppressant Drugs 
and the Risk of Cardiac-Valve Regurgitation, 339 NEW ENG. J. MED., 719-24 
(1998). Of note, this article included both observational cohort and case-control 
analyses within one manuscript; representing an uncommon, but suitable, 
format. 
8 Id. 
9 Id. 
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dexfenfluramine was associated with an increased risk of cardiac-
valve disorders reflects the analytic nature of the study. 
 
FIGURE 3B—SCHEMATIC OF CASE CONTROL ARCHITECTURE 
disease      no disease
Longitudinal assessment; start with outcome:
 
2.  Experimental Studies 
The hallmark of an experimental study is that exposure is 
assigned by a research investigator. In practical terms, a 
randomized controlled trial (or what could be called an 
experimental cohort) is the currently accepted experimental design 
in clinical research involving intact human beings. The importance 
of randomization is that it leads to a balance of risk factors in 
exposed and non-exposed groups, promoting an unbiased 
evaluation of exposure-outcome associations. An example of a 
randomized trial involving dietary supplements is an article that 
used data from an earlier randomized, controlled trial comparing 
the efficacy and safety of dexfenfluramine and placebo in treating 
obesity. 10 Taking advantage of previously collected data (before a 
possible link to heart diease was recognized), the authors reported 
a “small increase” in the prevalence of valvular disease in patients 
                                                          
10 Neil J. Weissman et al., An Assessment of Heart-Valve Abnormalities in 
Obese Patients Taking Dexfenfluramine, Sustained-Release Dexfenfluramine, or 
Placebo, 339 NEW ENG. J. MED., 725-32 (1998). It is self-evident that designing 
a clinical trial to assess the association between dietary supplements and 
valvular heart disease would be unethical. 
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treated with fenfluramine.11 
3.  Other Study Designs 
The research designs described in the previous sub-sections 
often go by different names, and many other types of research 
designs also exist. An example of another type of study is ecologic 
analysis, with data for geographic areas (e.g., countries) used in 
lieu of individual exposures. Other designs include meta analysis, 
in which mathematical pooling of available studies is done,12 and 
decision analysis, in which a mathematical model is used to 
simulate results for hypothetical patients, based on data from 
patient-based studies and other sources. 
III. FORMAT FOR REPORTING RESULTS 
A discussion of research design would benefit from a 
description of the common formats used for reporting their results. 
In brief, the results can be thought of as being quantitative 
(clinical) and statistical (probabilistic). Quantitative results address 
the strength of an association, whereas statistical results address 
the stability of an association. As an example of hypothetical 
results (Table 2), an association between exposure and disease 
among 2,000 patients can be considered. 
 
 
 
 
 
 
 
 
 
 
                                                          
11 Id. 
12 See John P.A. Ioannidis, M.D. & Joseph Lau, M.D., Systematic Review 
of Medica Evidence, 12 J.L. & POL’Y 509 (2004). 
CONCATOMACRO WITH FIGURES COMPLETE.DOC 4/23/2004  12:33 PM 
 RESEARCH DESIGN IN EPIDEMIOLOGY 499 
TABLE 2—EXAMPLE OF STATISTICAL RESULTS FOR 
HYPOTHETICAL STUDY 
60            940
30            970
Exposed 
Not exposed 
Disease     No disease           
Relative risk = (60/1000) ÷ (30/1000) = 6% ÷ 3% = 2.0;
95% confidence interval = 1.3 to 3.1; P = 0.001 
1000
1000
 
A. Quantitative Results 
A common format for reporting the quantitative strength of the 
association is the relative risk (Table 2), representing the rate of 
outcome among exposed patients (60/1000 = 6%), divided by the 
rate of outcome in the non-exposed group (30/1000 = 3%). The 
relative risk is calculated as 2.0 in this situation and would be 
stated as “exposed patients were twice as likely to have disease as 
non-exposed patients.” A relative risk of 1.0 would indicate no 
association (i.e., identical outcome rates for the compared groups), 
and is therefore called the null value. 
The results for this same hypothetical study can be reported, 
however, in many different ways. For example, the relative risk 
(just calculated as 2.0) is often replaced by other so-called point 
estimates, such as an odds ratio, hazard ratio, rate ratio, or rate per 
100 person-years of follow-up (e.g., 10 people for 10 years, or 50 
people for two years), depending on the particular research design. 
Even if one focuses on a relative risk, however, it should be 
appreciated that the comparison of 6% vs. 3% could be described 
as an absolute risk difference, calculated as (6% - 3% =) a 3% 
increase; or a proportionate difference, calculated as ([6% - 3%] ÷ 
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3% =) a 100% increase.13 In addition, other formats for reporting 
results have been devised, such as the number needed to treat (or in 
this situation, the number needed to harm).14 
Importantly, no single scientific threshold exists for 
quantitative significance, such as determining whether a 6% vs. 
3% outcome is big enough. In a legal context, however, a relative 
risk of greater than 2 has been cited as representing a situation 
where “were the exposures more likely than not the cause”15 of the 
outcome. The logic behind this statement is shown in Table 2, 
using the same hypothetical study. The explanation is that among 
the 60 patients who were exposed and who experienced the 
outcome, 30 would have the baseline rate (or expected) outcome, 
and 30 more could be attributed to the exposure. Thus, if more than 
60 patients are in the upper left hand cell, it is more likely than not 
that any given patient’s outcome is due to exposure. From an 
epidemiologic perspective, however, this threshold value of 2.0 is 
quite arbitrary. The results of any study are subject to statistical 
variation as well as bias, such that a relative risk of 2.1 vs. 1.9 
would not be considered substantially different by most 
epidemiologists. 
B. Statistical Results 
The same hypothetical study would typically have additional 
results reported in Probability (P) values or confidence intervals. In 
contrast to quantitative results, threshold values do exist for these 
statistical results. Specifically, a P value less than or equal to 0.05, 
and a 95% confidence interval that excludes 1.0 (or another null 
value) are used to determine that results are “statistically 
                                                          
13 Depending on one’s perspective—especially in a legal setting—one party 
might be inclined to report “only” a 3% increase, whereas the other party may 
claim a “whopping” 100% increase, for the exact same findings. 
14 Ignoring the mathematical calculations involved (1/[0.06 – 0.03] = 1/0.03 
= 33.3); the interpretation is that when approximately 33 patients are exposed 
(or not) in each arm of the study, one extra outcome would be observed in the 
exposed group 
15 FED. JUDICIAL CTR., REFERENCE MANUAL ON SCIENTIFIC EVIDENCE 384 
(2d ed. 2000). 
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significant.” 
1.  P Values 
A P value can be thought of as the probability of an observed 
result occurring by chance alone. The P value could range from 0 
to 1, where “lower is better,” and P less than or equal to 0.05 is a 
threshold value as mentioned previously. If the P value is equal to 
0.05, we are acknowledging that there is a 1 in 20 probability of 
the result occurring by chance alone, i.e., being a false-positive 
result. Using an example from the mathematical concept of 
probability, the P value for obtaining 5 consecutive heads when 
flipping a fair coin would be (0.5)5= 0.031, or approximately 3 in 
100. For 10 consecutive heads, the P value would be (0.5)10 = 
0.00098, or less than 1 in 1000. One might “worry” about a coin 
having two heads if heads appeared five times in a row, and even 
more so for ten times in a row, but either event could happen 
potentially. The corresponding interpretation of a study with P = 
0.031 would be that the observed result linking exposure to 
outcome was unlikely due to chance (less than 0.05); and the 
interpretation for a study with P = 0.00098 would be that the 
observed result was very unlikely to represent a chance occurrence 
(much less than 0.05). The calculated P value for the data in Table 
2 is 0.001, indicating a statistically significant (stable) result. 
2.  Confidence Intervals 
The results from Table 2 are illustrated again in Figure 4, 
showing the relative risk of 2.0 and a 95% confidence interval 
from 1.3 - 3.1; indicating the strength of association may be as low 
as 1.3 or as high as 3.1, but the best estimate is 2.0. In this manner, 
confidence intervals are shown to express stability of results in 
terms of “units” of relative risk (or other point estimates), based on 
the same mathematical information as P values. For example, the 
observation that the entire 95% confidence interval, including the 
lower bound at 1.3, does not overlap the null value of a relative 
risk of 1.0, indicates a statistically significant exposure-outcome 
association (P < 0.05). 
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FIGURE 4—P VALUE AND 95% CONFIDENCE INTERVAL (C.I.) 
FOR TABLE 2 
Relative risk = 2.0; 95% C.I. = 1.3-3.1; P = 0.001
P < 0.05 
decreased risk ← → increased risk
Note that if RR = 1.0, no exposure-outcome
association exists.
relative risk = 1                  2                  3 
 
 
The general relationship of P values and confidence intervals is 
shown in Figure 5; e.g., if a P value is greater than 0.05 (not 
statistically significant), the 95% confidence interval includes the 
null value of one. 
 
FIGURE 5—RELATIONSHIP OF P VALUES AND 95% CONFIDENCE 
INTERVALS 
Relative risk = 1                   2                   3                   
P < 0.05 
P > 0.05
P = 0.05
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3.  Other Considerations 
A more in-depth understanding of statistical results can be 
aided by evaluating “results” from baseball. When evaluating a 
comparison of batting averages, one can consider whether a .333 
average is better than a .250 average (Table 3). The answer would 
almost certainly be “yes” regarding the quantitative difference, but 
most people would agree that results would be unstable (i.e., not 
likely to persist) if based, respectively, on 1 hit in 3 at-bats vs. 1 hit 
in 4 at-bats, perhaps based on one game at the end of the previous 
season. That instability is represented by a calculated P value of 
0.81. Importantly, the P value decreases for the same comparison 
of batting averages as the denominator (number of at bats) 
increases. Thus, by the time these players have 300 and 400 at 
bats, respectively, the P value of 0.02 indicates that that difference 
is unlikely due to chance. If the batters end up having several 
thousand at-bats over the course of their career, the P value shrinks 
to a very small number (less than 0.0000001) shown in Table 3; 
indicating that the averages are unlikely to be the same, even if the 
.333 batter went in to a prolonged slump, and the .250 batter had a 
sustained hitting streak. The take-home message is that the larger 
the sample size, the smaller the P value, for constant proportions 
being compared. 
 
TABLE 3—EXAMPLE OF “LARGE” QUANTITATIVE DIFFERENCE 
Player A = .333 Player B = .250 P Value
1/3 1/4 0.81
10/30 10/40                            0.45
100/300 100/400                          0.02  
1000/3000 1000/4000                 <0.0000001
Note: The larger the sample size, the smaller the P value, 
for constant proportions.  
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A second example involving batting averages illustrates the 
same issue, with a different perspective (Table 4). In this scenario, 
one player has a .288 batting average, where as the second player 
has a .282 batting average. The P value of 0.77 indicates that the 
two numbers are not statistically significantly different based on 
1,000 at bats; and the difference might not have been considered 
quantitatively important to start with. Yet, if the number of at-bats 
is increased sufficiently, up to (an unrealistic) value of 100,000, a 
P value of 0.003 can be obtained. The take-home message here is 
that a quantitatively unimportant difference can be statistically 
significant (i.e., less than 0.05), with a large enough sample size. 
These examples illustrate that a P value and or confidence intervals 
can help in evaluating the stability of results, but they do not 
themselves address directly the validity or trustworthiness of the 
data. 
 
TABLE 4—EXAMPLE OF “SMALL” QUALITATIVE DIFFERENCE 
Player A = .288 Player B = .282 P Value
288/1000 282/1000 0.77
2,880/10,000 2,820/10,000                      0.35
28,800/100,000     28,200/100,000                   0.003
Note: A quantitatively unimportant difference can be made
statistically significant, with a large enough sample size.
 
IV. STRENGTHS AND LIMITATIONS OF STRATEGIES IN 
EPIDEMIOLOGY 
An overview of the strategies used in epidemiology can be 
discussed in terms of the four stages of analytic study assessing 
probabilistic causation: framing a research question; developing a 
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study design;16 collecting data; and completing a statistical 
analysis.17 
A. Framing a Research Question 
Issues regarding framing the research question include whether 
the topic is relevant and whether the question being posed is 
cogent. In medical research, the assessment of importance is often 
determined via granting agencies (e.g., the National Institutes of 
Health) that provide funding to investigators, or the peer review 
process that determines which manuscripts are published in various 
medical journals. In legal settings, the adjudication of a 
controversy in the courtroom would indicate de facto a substantial 
level of importance. Questions and controversies may still arise, 
however, regarding, for example, how to interpret studies that 
examined similar, but not identical, dietary suppressant drugs, or 
studies that did not perform standard diagnostic tests to find 
valvular disease among all patients, etc. 
B. Developing a Study Design 
Randomized controlled trials are less vulnerable to 
confounding when compared to observational studies because 
randomization balances potential confounding factors with regard 
to exposure. In this context, the conventional wisdom for the past 
several decades has been that observational studies are always 
inferior to randomized trials, due largely to the problem of 
confounding. Work done by our group and others,18 however, has 
shown that contrary to prevailing beliefs, results from well-
                                                          
16 See supra Part II. 
17 See supra Part III. 
18 Kjell Benson & Arthur J. Hartz, A Comparison of Observational Studies 
and Randomized, Controlled Trials, 342 NEW ENG. J. MED., 1878-86 (2000); 
John Concato et al., Randomized, Controlled Trials, Observational Studies, and 
the Hierarchy of Research Designs, 342 NEW ENG. J. MED., 1887-92 (2000); 
Martin McKee, et al., Methods in Health Services Research: Interpreting the 
Evidence: Choosing Between Randomised and Non-Randomised Studies, 319 
BRIT. MED. J. 312-5 (1999). 
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designed observational studies (with a cohort or case-control 
design) did not systematically overestimate the magnitude of the 
associations between exposure and outcome compared with 
randomized, controlled trials. The results suggested that suitable 
precautions against bias were taken in higher quality observational 
studies, making them comparable to clinical trials in terms of 
producing valid results. 
This work indicates that epidemiologistsand judgesshould 
be flexible in interpreting evidence from various types of study 
design. Unfortunately, it is not a simple matter to determine 
whether a particular study is valid or not. Various lists (e.g., using 
“evidence-based medicine”)19 that attempt to provide a hierarchical 
assessment of research design should be viewed with caution. 
C. Collecting Data 
Data collection is a frequently overlooked activity, often with 
assumptions that the activity has been done in a trustworthy 
manner. Yet, it is important to note that high quality data are 
crucial to ensure the validity of a study, and such data can involve 
considerable effort to obtain. For example, large databases often 
collect information for one purpose (e.g., health insurance 
documentation) and are used for another (medical research), with 
incomplete measurements for the factors of interest.20 In contrast, a 
review of medical records, or direct examination of patients, might 
be more difficult and expensive, but more appropriate. In legal 
settings, the collection of data can become an intense focus of 
scrutiny, with the motives of investigators called into question. 
D. Statistical Analysis 
In terms of assuring that a study is done well, statistical 
analyses, per se, areperhaps surprisinglynot a critical issue, in 
                                                          
19 Evidence-Based Medicine Working Group, Evidence-Based Medicine: a 
New Approach to Teaching the Practice of Medicine, 268 J. AM. MED. ASS’N 
2420-25 (1992). 
20 See, e.g., John Concato et al., Problems of Comorbidity in Mortality after 
Prostatectomy, 267 J. AM. MED. ASS’N 1077-82 (1992). 
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most situations. The most difficult aspect of statistical analyses can 
be understanding what particular statistical test (procedure) was 
used, and why.21 Regardless of the statistical test, however, a point 
estimate, and a P value or confidence interval, is usually generated 
as a final product of the analysis. Although a particular statistical 
approach might obscure the understanding of a study’s results, a 
competent biostatistician or other professional with suitable 
training should be able to describe the process in “plain English.” 
 
CONCLUSION 
Epidemiology is a rigorous and important scientific discipline, 
but “truth” is difficult to establish. Specifically, studies differ 
regarding characteristics of patients, assessments of exposure and 
outcome, possible sources of methodololgical bias, as well as the 
potential influence of personal or political views. Contradictory 
results from multiple epidemiologic studies should therefore be 
resolved by scientific process of reconciling disagreement (e.g., 
evaluating the quality of research methods). This process, 
challenging under any circumstances, is made more complex when 
legal issues are involved. 
 
                                                          
21 See John Concato et al., The Risk of Determining Risk with Multivariable 
Models, 118 ANNALS INTERNAL MED. 201-10 (1993) (discussing popular 
techniques). 
